Identification

Name
Atracurium besylate
Accession Number
DB00732  (APRD00806)
Type
Small Molecule
Groups
Approved
Description

A non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents. [PubChem]

Structure
Thumb
Synonyms
  • 1-[(3,4-Dimethoxyphenyl)methyl]-2-[3-({5-[(3-{1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium-2-yl}propanoyl)oxy]pentyl}oxy)-3-oxopropyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium
  • Atracurium besilate
  • Atracurium dibesylate
External IDs
BW 33A / BW-33A / Wellcome 33-A-74
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Atracurium - (for Single Dose )Solution10 mgIntravenousIvax Pharmaceuticals IncorporatedNot applicableNot applicableCanada
Atracurium - (for Multiple Dose Vial - With Preservative)Solution10 mgIntravenousIvax Pharmaceuticals IncorporatedNot applicableNot applicableCanada
Atracurium Besylate InjectionLiquid10 mgIntravenousSandoz Canada Incorporated1998-01-20Not applicableCanada
Atracurium Besylate InjectionSolution10 mgIntravenousHospira, Inc.1998-07-132012-08-03Canada
Atracurium Besylate InjectionLiquid10 mgIntravenousAbbott1998-02-112007-07-31Canada
TracriumLiquid10 mgIntravenousAbbvie1990-12-312012-11-03Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Atracurium BesylateInjection, solution50 mg/5mLIntravenousAuro Medics Pharma Llc2015-04-08Not applicableUs
Atracurium BesylateInjection, solution10 mg/mLIntravenousMylan Institutional2017-10-19Not applicableUs
Atracurium BesylateInjection, solution10 mg/mLIntravenousSagent Pharmaceuticals2012-05-01Not applicableUs
Atracurium BesylateInjection, solution10 mg/mLIntravenousMeitheal Pharmaceuticals Inc.2018-05-15Not applicableUs
Atracurium BesylateInjection, solution50 mg/5mLIntravenousAurobindo Pharma2015-04-08Not applicableUs
Atracurium BesylateInjection, solution10 mg/mLIntravenousHospira, Inc.2012-10-18Not applicableUs
Atracurium BesylateInjection, solution10 mg/mLIntravenousSagent Pharmaceuticals2012-05-01Not applicableUs
Atracurium BesylateInjection, solution100 mg/10mLIntravenousAuro Medics Pharma Llc2015-04-08Not applicableUs
Atracurium BesylateInjection, solution10 mg/mLIntravenousMylan Institutional2017-10-19Not applicableUs
Atracurium BesylateInjection, solution10 mg/mLIntravenousHospira, Inc.2012-10-18Not applicableUs
Categories
UNII
40AX66P76P
CAS number
64228-81-5
Weight
Average: 1243.49
Monoisotopic: 1242.500406156
Chemical Formula
C65H82N2O18S2
InChI Key
XXZSQOVSEBAPGS-UHFFFAOYSA-L
InChI
InChI=1S/C53H72N2O12.2C6H6O3S/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6;2*7-10(8,9)6-4-2-1-3-5-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3;2*1-5H,(H,7,8,9)/q+2;;/p-2
IUPAC Name
1-[(3,4-dimethoxyphenyl)methyl]-2-[3-({5-[(3-{1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium-2-yl}propanoyl)oxy]pentyl}oxy)-3-oxopropyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium dibenzenesulfonate
SMILES
[O-]S(=O)(=O)C1=CC=CC=C1.[O-]S(=O)(=O)C1=CC=CC=C1.COC1=CC2=C(C=C1OC)C(CC1=CC(OC)=C(OC)C=C1)[N+](C)(CCC(=O)OCCCCCOC(=O)CC[N+]1(C)CCC3=C(C=C(OC)C(OC)=C3)C1CC1=CC(OC)=C(OC)C=C1)CC2

Pharmacology

Indication

For use, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Associated Therapies
Pharmacodynamics

Atracurium is a nondepolarizing skeletal muscle relaxant. Atracurium can be used most advantageously if muscle twitch response to peripheral nerve stimulation is monitored to assess degree of muscle relaxation. The duration of neuromuscular block produced by Atracurium is approximately one third to one half the duration of block by d-tubocurarine, metocurine, and pancuronium at initially equipotent doses. As with other nondepolarizing neuromuscular blockers, the time to onset of paralysis decreases and the duration of maximum effect increases with increasing doses of Atracurium. Repeated administration of maintenance doses of Atracurium has no cumulative effect on the duration of neuromuscular block if recovery is allowed to begin prior to repeat dosing. Moreover, the time needed to recover from repeat doses does not change with additional doses. Repeat doses can therefore be administered at relatively regular intervals with predictable results.

Mechanism of action

Atracurium antagonizes the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate. This antagonism is inhibited, and neuromuscular block reversed, by acetylcholinesterase inhibitors such as neostigmine, edrophonium, and pyridostigmine.

TargetActionsOrganism
ANeuronal acetylcholine receptor subunit alpha-2
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life

The elimination half-life is approximately 20 minutes.

Clearance
Not Available
Toxicity

Excessive doses can be expected to produce enhanced pharmacological effects. Overdosage may increase the risk of histamine release and cardiovascular effects, especially hypotension.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with 1,10-Phenanthroline.Experimental
16-BromoepiandrosteroneAtracurium besylate may increase the adverse neuromuscular activities of 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneAtracurium besylate may increase the adverse neuromuscular activities of 19-norandrostenedione.Experimental, Illicit
5-androstenedioneAtracurium besylate may increase the adverse neuromuscular activities of 5-androstenedione.Experimental, Illicit
AcetyldigitoxinAtracurium besylate may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
AcetyldigoxinAtracurium besylate may increase the arrhythmogenic activities of Acetyldigoxin.Experimental
AclidiniumAtracurium besylate may increase the anticholinergic activities of Aclidinium.Approved
AgmatineAgmatine may increase the neuromuscular blocking activities of Atracurium besylate.Experimental, Investigational
AlclometasoneAtracurium besylate may increase the adverse neuromuscular activities of Alclometasone.Approved
AlcuroniumThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Alcuronium.Experimental
AldosteroneAtracurium besylate may increase the adverse neuromuscular activities of Aldosterone.Experimental, Investigational
AlfentanilThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Alphaprodine.Illicit
AmbenoniumThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Ambenonium.Approved
AmcinonideAtracurium besylate may increase the adverse neuromuscular activities of Amcinonide.Approved
AmikacinThe therapeutic efficacy of Atracurium besylate can be increased when used in combination with Amikacin.Approved, Investigational, Vet Approved
AmiodaroneAmiodarone may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational
AmlodipineAmlodipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AndrostenedioneAtracurium besylate may increase the adverse neuromuscular activities of Androstenedione.Experimental, Illicit
AnecortaveAtracurium besylate may increase the adverse neuromuscular activities of Anecortave.Investigational
anecortave acetateAtracurium besylate may increase the adverse neuromuscular activities of anecortave acetate.Investigational
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Atracurium besylate.Approved
ApramycinApramycin may increase the respiratory depressant activities of Atracurium besylate.Experimental, Vet Approved
AranidipineAranidipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational
ArbekacinArbekacin may increase the respiratory depressant activities of Atracurium besylate.Approved, Investigational
AtamestaneAtracurium besylate may increase the adverse neuromuscular activities of Atamestane.Investigational
AtracuriumThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Atracurium.Approved, Experimental, Investigational
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Atracurium besylate.Approved, Vet Approved
AzelnidipineAzelnidipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational
AzosemideAzosemide may decrease the neuromuscular blocking activities of Atracurium besylate.Investigational
BarnidipineBarnidipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
Beclomethasone dipropionateThe risk or severity of myopathy and weakness can be increased when Atracurium besylate is combined with Beclomethasone dipropionate.Approved, Investigational
BekanamycinBekanamycin may increase the respiratory depressant activities of Atracurium besylate.Experimental
BenactyzineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Benactyzine.Withdrawn
BencyclaneBencyclane may increase the neuromuscular blocking activities of Atracurium besylate.Experimental
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Atracurium besylate.Approved
BenidipineBenidipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Atracurium besylate.Approved
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Atracurium besylate.Approved, Illicit
BenzthiazideThe serum concentration of Benzthiazide can be increased when it is combined with Atracurium besylate.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Atracurium besylate.Approved
BepridilBepridil may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Withdrawn
BetamethasoneAtracurium besylate may increase the adverse neuromuscular activities of Betamethasone.Approved, Vet Approved
BezitramideThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Bezitramide.Experimental, Illicit, Withdrawn
BioallethrinBioallethrin may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Experimental
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Atracurium besylate.Approved, Investigational
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Atracurium besylate.Experimental
Botulinum Toxin Type ABotulinum Toxin Type A may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational
Botulinum Toxin Type BAtracurium besylate may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Atracurium besylate.Approved
BudesonideThe risk or severity of myopathy and weakness can be increased when Atracurium besylate is combined with Budesonide.Approved
BumetanideBumetanide may decrease the neuromuscular blocking activities of Atracurium besylate.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Atracurium besylate.Approved
ButorphanolThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Butorphanol.Approved, Illicit, Vet Approved
ButylscopolamineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Butylscopolamine.Approved, Investigational, Vet Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Atracurium besylate.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Atracurium besylate.Approved, Investigational
CarboxyamidotriazoleCarboxyamidotriazole may increase the neuromuscular blocking activities of Atracurium besylate.Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Carfentanil.Illicit, Investigational, Vet Approved
CaroverineCaroverine may increase the neuromuscular blocking activities of Atracurium besylate.Experimental
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Atracurium besylate.Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Atracurium besylate.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Atracurium besylate.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Chlorphenoxamine.Withdrawn
ChlortetracyclineChlortetracycline may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational, Vet Approved
ChlorthalidoneChlorthalidone may decrease the neuromuscular blocking activities of Atracurium besylate.Approved
CiclesonideAtracurium besylate may increase the adverse neuromuscular activities of Ciclesonide.Approved, Investigational
CilnidipineCilnidipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational
CimetropiumAtracurium besylate may increase the anticholinergic activities of Cimetropium.Experimental, Investigational
CinnarizineCinnarizine may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Atracurium besylate.Approved, Investigational
ClevidipineClevidipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational
ClindamycinThe therapeutic efficacy of Atracurium besylate can be increased when used in combination with Clindamycin.Approved, Vet Approved
ClobetasolAtracurium besylate may increase the adverse neuromuscular activities of Clobetasol.Approved, Investigational
Clobetasol propionateAtracurium besylate may increase the adverse neuromuscular activities of Clobetasol propionate.Approved
ClobetasoneAtracurium besylate may increase the adverse neuromuscular activities of Clobetasone.Approved
ClocortoloneAtracurium besylate may increase the adverse neuromuscular activities of Clocortolone.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Atracurium besylate.Approved, Illicit
ColistimethateColistimethate may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Vet Approved
Cortexolone 17α-propionateAtracurium besylate may increase the adverse neuromuscular activities of Cortexolone 17α-propionate.Investigational
CorticosteroneAtracurium besylate may increase the adverse neuromuscular activities of Corticosterone.Experimental
Cortisone acetateAtracurium besylate may increase the adverse neuromuscular activities of Cortisone acetate.Approved, Investigational
CoumaphosThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Coumaphos.Vet Approved
CyclandelateCyclandelate may increase the neuromuscular blocking activities of Atracurium besylate.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Atracurium besylate.Approved
CyclopenthiazideThe serum concentration of Cyclopenthiazide can be increased when it is combined with Atracurium besylate.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Atracurium besylate.Approved
CyclosporineThe therapeutic efficacy of Atracurium besylate can be increased when used in combination with Cyclosporine.Approved, Investigational, Vet Approved
CymarinAtracurium besylate may increase the arrhythmogenic activities of Cymarin.Experimental
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Atracurium besylate.Approved, Investigational
DarodipineDarodipine may increase the neuromuscular blocking activities of Atracurium besylate.Experimental
DecamethoniumThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Decamethonium.Approved
DeflazacortAtracurium besylate may increase the adverse neuromuscular activities of Deflazacort.Approved, Investigational
DemecariumThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Demecarium.Approved
DemeclocyclineDemeclocycline may increase the neuromuscular blocking activities of Atracurium besylate.Approved
DesfluraneDesflurane may increase the neuromuscular blocking activities of Atracurium besylate.Approved
DeslanosideAtracurium besylate may increase the arrhythmogenic activities of Deslanoside.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Desloratadine.Approved, Investigational
DesonideAtracurium besylate may increase the adverse neuromuscular activities of Desonide.Approved, Investigational
DesoximetasoneAtracurium besylate may increase the adverse neuromuscular activities of Desoximetasone.Approved
Desoxycorticosterone acetateAtracurium besylate may increase the adverse neuromuscular activities of Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateAtracurium besylate may increase the adverse neuromuscular activities of Desoxycorticosterone Pivalate.Experimental, Vet Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Desvenlafaxine.Approved, Investigational
DexamethasoneThe risk or severity of myopathy and weakness can be increased when Atracurium besylate is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateAtracurium besylate may increase the adverse neuromuscular activities of Dexamethasone isonicotinate.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Atracurium besylate.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Atracurium besylate.Withdrawn
DexniguldipineDexniguldipine may increase the neuromuscular blocking activities of Atracurium besylate.Experimental
DextromethorphanThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DexverapamilDexverapamil may increase the neuromuscular blocking activities of Atracurium besylate.Experimental
DezocineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Dezocine.Approved, Investigational
DibekacinDibekacin may increase the respiratory depressant activities of Atracurium besylate.Experimental
DichlorvosThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Dichlorvos.Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Atracurium besylate.Approved
Diethyl etherDiethyl ether may increase the neuromuscular blocking activities of Atracurium besylate.Experimental
DiflorasoneAtracurium besylate may increase the adverse neuromuscular activities of Diflorasone.Approved
DifluocortoloneAtracurium besylate may increase the adverse neuromuscular activities of Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateAtracurium besylate may increase the adverse neuromuscular activities of Difluprednate.Approved
DigitoxinAtracurium besylate may increase the arrhythmogenic activities of Digitoxin.Approved, Investigational
DigoxinAtracurium besylate may increase the arrhythmogenic activities of Digoxin.Approved
Digoxin Immune Fab (Ovine)Atracurium besylate may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Dihydromorphine.Experimental, Illicit
DihydrostreptomycinDihydrostreptomycin may increase the respiratory depressant activities of Atracurium besylate.Investigational, Vet Approved
DiltiazemDiltiazem may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Atracurium besylate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Atracurium besylate.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Diphenoxylate.Approved, Illicit
DipivefrinThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Dipivefrin.Approved
DistigmineThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Distigmine.Experimental
DonepezilThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Donepezil.Approved
DotarizineDotarizine may increase the neuromuscular blocking activities of Atracurium besylate.Investigational
DoxycyclineDoxycycline may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Atracurium besylate.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with DPDPE.Experimental
DronabinolAtracurium besylate may increase the tachycardic activities of Dronabinol.Approved, Illicit
EchothiophateThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Echothiophate.Approved
EdrophoniumThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Edrophonium.Approved
EfonidipineEfonidipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational
EluxadolineAtracurium besylate may increase the constipating activities of Eluxadoline.Approved, Investigational
EmeproniumThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Emepronium.Experimental
EmopamilEmopamil may increase the neuromuscular blocking activities of Atracurium besylate.Experimental
EnfluraneEnflurane may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational, Vet Approved
EperisoneEperisone may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational
EpitizideThe serum concentration of Epitizide can be increased when it is combined with Atracurium besylate.Experimental
EquileninAtracurium besylate may increase the adverse neuromuscular activities of Equilenin.Experimental
EquilinAtracurium besylate may increase the adverse neuromuscular activities of Equilin.Approved
EstroneAtracurium besylate may increase the adverse neuromuscular activities of Estrone.Approved
Estrone sulfateAtracurium besylate may increase the adverse neuromuscular activities of Estrone sulfate.Approved
Etacrynic acidEtacrynic acid may decrease the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational
EtanautineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Etanautine.Experimental
EthanolAtracurium besylate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Atracurium besylate.Approved
EthosuximideEthosuximide may increase the neuromuscular blocking activities of Atracurium besylate.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Ethylmorphine.Approved, Illicit
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Atracurium besylate.Approved
EtorphineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Etybenzatropine.Experimental
FelodipineFelodipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational
FendilineFendiline may increase the neuromuscular blocking activities of Atracurium besylate.Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Atracurium besylate.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Fenthion.Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Fesoterodine.Approved
Fish oilFish oil may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Nutraceutical
FlavoxateThe risk or severity of adverse effects can be increased when Flavoxate is combined with Atracurium besylate.Approved
FluasteroneAtracurium besylate may increase the adverse neuromuscular activities of Fluasterone.Investigational
FludrocortisoneAtracurium besylate may increase the adverse neuromuscular activities of Fludrocortisone.Approved, Investigational
FlumethasoneAtracurium besylate may increase the adverse neuromuscular activities of Flumethasone.Approved, Vet Approved
FlunarizineFlunarizine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
FlunisolideAtracurium besylate may increase the adverse neuromuscular activities of Flunisolide.Approved, Investigational
Fluocinolone AcetonideAtracurium besylate may increase the adverse neuromuscular activities of Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideAtracurium besylate may increase the adverse neuromuscular activities of Fluocinonide.Approved, Investigational
FluocortoloneAtracurium besylate may increase the adverse neuromuscular activities of Fluocortolone.Approved, Withdrawn
FluorometholoneAtracurium besylate may increase the adverse neuromuscular activities of Fluorometholone.Approved, Investigational
FluoxetineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Fluoxetine.Approved, Vet Approved
FluprednideneAtracurium besylate may increase the adverse neuromuscular activities of Fluprednidene.Approved, Withdrawn
FluprednisoloneAtracurium besylate may increase the adverse neuromuscular activities of Fluprednisolone.Approved
FlurandrenolideAtracurium besylate may increase the adverse neuromuscular activities of Flurandrenolide.Approved
FluspirileneFluspirilene may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational
FluticasoneAtracurium besylate may increase the adverse neuromuscular activities of Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateAtracurium besylate may increase the adverse neuromuscular activities of Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Atracurium besylate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Fluvoxamine.Approved, Investigational
FormestaneAtracurium besylate may increase the adverse neuromuscular activities of Formestane.Approved, Investigational, Withdrawn
FosphenytoinFosphenytoin may decrease the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational
FramycetinFramycetin may increase the respiratory depressant activities of Atracurium besylate.Approved
FurosemideFurosemide may decrease the neuromuscular blocking activities of Atracurium besylate.Approved, Vet Approved
GabapentinGabapentin may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational
GalantamineThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Galantamine.Approved
GallamineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Gallamine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Atracurium besylate.Approved
GallopamilGallopamil may increase the neuromuscular blocking activities of Atracurium besylate.Investigational
GeneticinGeneticin may increase the respiratory depressant activities of Atracurium besylate.Experimental
GentamicinGentamicin may increase the respiratory depressant activities of Atracurium besylate.Approved, Vet Approved
GENTAMICIN C1AGENTAMICIN C1A may increase the respiratory depressant activities of Atracurium besylate.Experimental
Ginkgo bilobaThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Ginkgo biloba.Approved, Investigational, Nutraceutical
GitoformateAtracurium besylate may increase the arrhythmogenic activities of Gitoformate.Experimental
Glucagon recombinantThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Glucagon recombinant.Approved
GlycopyrroniumAtracurium besylate may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Atracurium besylate.Approved, Investigational
HalcinonideAtracurium besylate may increase the adverse neuromuscular activities of Halcinonide.Approved, Investigational, Withdrawn
HalothaneHalothane may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Vet Approved
HE3286Atracurium besylate may increase the adverse neuromuscular activities of HE3286.Investigational
HeroinThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Heroin.Approved, Illicit, Investigational
HomatropineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Homatropine.Approved
Huperzine AThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Huperzine A.Approved, Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Atracurium besylate.Approved, Vet Approved
HydrocodoneAtracurium besylate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe risk or severity of myopathy and weakness can be increased when Atracurium besylate is combined with Hydrocortisone.Approved, Vet Approved
Hydrocortisone acetateThe risk or severity of myopathy and weakness can be increased when Atracurium besylate is combined with Hydrocortisone acetate.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of myopathy and weakness can be increased when Atracurium besylate is combined with Hydrocortisone butyrate.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may decrease the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Hydromorphone.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Atracurium besylate.Approved
Hygromycin BHygromycin B may increase the respiratory depressant activities of Atracurium besylate.Vet Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Atracurium besylate.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Atracurium besylate.Approved
IpidacrineThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Ipidacrine.Experimental
IpratropiumThe risk or severity of adverse effects can be increased when Ipratropium is combined with Atracurium besylate.Approved
IsepamicinIsepamicin may increase the respiratory depressant activities of Atracurium besylate.Experimental
IsofluraneIsoflurane may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Vet Approved
IsoflurophateThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Isoflurophate.Approved, Investigational, Withdrawn
IsradipineIsradipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational
IstaroximeAtracurium besylate may increase the adverse neuromuscular activities of Istaroxime.Investigational
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Atracurium besylate.Investigational
KanamycinKanamycin may increase the respiratory depressant activities of Atracurium besylate.Approved, Investigational, Vet Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Ketobemidone.Approved, Investigational
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Atracurium besylate.Approved
LacidipineLacidipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational
LamotrigineLamotrigine may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational
Lanatoside CAtracurium besylate may increase the arrhythmogenic activities of Lanatoside C.Experimental
LercanidipineLercanidipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational
LevetiracetamLevetiracetam may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Atracurium besylate.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Levomethadyl Acetate.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Levorphanol.Approved
LidoflazineLidoflazine may increase the neuromuscular blocking activities of Atracurium besylate.Experimental
LincomycinLincomycin may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Vet Approved
Lithium cationLithium may increase the neuromuscular blocking activities of Atracurium besylate.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Lofentanil.Illicit
LomerizineLomerizine may increase the neuromuscular blocking activities of Atracurium besylate.Experimental
LoperamideLoperamide may increase the neuromuscular blocking activities of Atracurium besylate.Approved
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Atracurium besylate.Approved, Investigational
LoteprednolAtracurium besylate may increase the adverse neuromuscular activities of Loteprednol.Approved
Magnesium carbonateThe therapeutic efficacy of Atracurium besylate can be increased when used in combination with Magnesium carbonate.Approved, Investigational
Magnesium citrateThe therapeutic efficacy of Atracurium besylate can be increased when used in combination with Magnesium citrate.Approved
Magnesium hydroxideThe therapeutic efficacy of Atracurium besylate can be increased when used in combination with Magnesium hydroxide.Approved, Investigational
Magnesium oxideMagnesium oxide may increase the neuromuscular blocking activities of Atracurium besylate.Approved
Magnesium salicylateMagnesium salicylate may increase the neuromuscular blocking activities of Atracurium besylate.Approved
Magnesium sulfateThe therapeutic efficacy of Atracurium besylate can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe therapeutic efficacy of Atracurium besylate can be increased when used in combination with Magnesium Trisilicate.Approved
MalathionThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Malathion.Approved, Investigational
ManidipineManidipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational
MazaticolThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Mazaticol.Experimental
ME-609Atracurium besylate may increase the adverse neuromuscular activities of ME-609.Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Atracurium besylate.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Atracurium besylate.Approved
MedrysoneAtracurium besylate may increase the adverse neuromuscular activities of Medrysone.Approved
MefloquineThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Mefloquine.Approved, Investigational
MelengestrolAtracurium besylate may increase the adverse neuromuscular activities of Melengestrol.Vet Approved
MemantineThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Memantine.Approved, Investigational
MentholMenthol may increase the neuromuscular blocking activities of Atracurium besylate.Approved
MeptazinolThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Meptazinol.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Methadyl Acetate.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Methantheline.Approved, Investigational
MethoxyfluraneMethoxyflurane may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational, Vet Approved
MethscopolamineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Methscopolamine.Approved
MethsuximideMethsuximide may increase the neuromuscular blocking activities of Atracurium besylate.Approved
MethyclothiazideMethyclothiazide may decrease the neuromuscular blocking activities of Atracurium besylate.Approved
MethylprednisoloneThe risk or severity of myopathy and weakness can be increased when Atracurium besylate is combined with Methylprednisolone.Approved, Vet Approved
Methylscopolamine bromideThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Methylscopolamine bromide.Approved
MetildigoxinAtracurium besylate may increase the arrhythmogenic activities of Metildigoxin.Experimental
MetixeneThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Metixene.Approved
MetoclopramideThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Atracurium besylate.Approved
MianserinMianserin may increase the anticholinergic activities of Atracurium besylate.Approved, Investigational
MibefradilMibefradil may increase the neuromuscular blocking activities of Atracurium besylate.Investigational, Withdrawn
MicronomicinMicronomicin may increase the respiratory depressant activities of Atracurium besylate.Experimental
MinaprineThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Minaprine.Approved
MinocyclineMinocycline may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational
MirabegronThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Mirabegron.Approved
MometasoneAtracurium besylate may increase the adverse neuromuscular activities of Mometasone.Approved, Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Morphine.Approved, Investigational
NabiloneAtracurium besylate may increase the tachycardic activities of Nabilone.Approved, Investigational
NaftopidilNaftopidil may increase the neuromuscular blocking activities of Atracurium besylate.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Nalbuphine.Approved
NCX 1022Atracurium besylate may increase the adverse neuromuscular activities of NCX 1022.Investigational
NeamineNeamine may increase the respiratory depressant activities of Atracurium besylate.Experimental
NeomycinThe therapeutic efficacy of Atracurium besylate can be increased when used in combination with Neomycin.Approved, Vet Approved
NeostigmineThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NetilmicinNetilmicin may increase the respiratory depressant activities of Atracurium besylate.Approved, Investigational
NicardipineNicardipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational
NicomorphineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Nicomorphine.Experimental
NifedipineNifedipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
NiguldipineNiguldipine may increase the neuromuscular blocking activities of Atracurium besylate.Experimental
NiludipineNiludipine may increase the neuromuscular blocking activities of Atracurium besylate.Experimental
NilvadipineNilvadipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational
NimesulideNimesulide may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational
NisoldipineNisoldipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
NitrendipineNitrendipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational
Nitrous oxideNitrous oxide may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Normethadone.Approved, Illicit
NylidrinNylidrin may increase the neuromuscular blocking activities of Atracurium besylate.Approved
OleandrinAtracurium besylate may increase the arrhythmogenic activities of Oleandrin.Experimental, Investigational
Oleoyl-estroneAtracurium besylate may increase the adverse neuromuscular activities of Oleoyl-estrone.Investigational
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Atracurium besylate.Approved
OpiumThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Opium.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Orphenadrine.Approved
OtiloniumOtilonium may increase the neuromuscular blocking activities of Atracurium besylate.Experimental, Investigational
OuabainAtracurium besylate may increase the arrhythmogenic activities of Ouabain.Approved
OxitropiumThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Oxitropium.Investigational
OxybutyninThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Atracurium besylate.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Atracurium besylate.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Atracurium besylate.Approved
OxytetracyclineOxytetracycline may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational, Vet Approved
PancuroniumThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Pancuronium.Approved
ParamethasoneAtracurium besylate may increase the adverse neuromuscular activities of Paramethasone.Approved
ParaoxonThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Paraoxon.Experimental
ParomomycinThe therapeutic efficacy of Atracurium besylate can be increased when used in combination with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Paroxetine.Approved, Investigational
PenfluridolPenfluridol may increase the neuromuscular blocking activities of Atracurium besylate.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Pentazocine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Pentolinium.Approved
PeruvosideAtracurium besylate may increase the arrhythmogenic activities of Peruvoside.Experimental
PethidineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Phenazocine.Experimental
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Atracurium besylate.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Atracurium besylate.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Phenoperidine.Experimental
PhenytoinPhenytoin may decrease the neuromuscular blocking activities of Atracurium besylate.Approved, Vet Approved
PhysostigmineThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Physostigmine.Approved, Investigational
PinaveriumPinaverium may increase the neuromuscular blocking activities of Atracurium besylate.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Pipecuronium.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Atracurium besylate.Approved
PiretanidePiretanide may decrease the neuromuscular blocking activities of Atracurium besylate.Approved
PiritramideThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Piritramide.Approved, Investigational
PirlimycinPirlimycin may increase the neuromuscular blocking activities of Atracurium besylate.Vet Approved
PlazomicinPlazomicin may increase the respiratory depressant activities of Atracurium besylate.Approved, Investigational
Polymyxin B SulfateThe therapeutic efficacy of Atracurium besylate can be increased when used in combination with Polymyxin B Sulfate.Approved, Vet Approved
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Atracurium besylate.Approved
PramipexoleAtracurium besylate may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintidePramlintide may increase the anticholinergic activities of Atracurium besylate.Approved, Investigational
PrasteroneAtracurium besylate may increase the adverse neuromuscular activities of Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateAtracurium besylate may increase the adverse neuromuscular activities of Prasterone sulfate.Investigational
PrednicarbateAtracurium besylate may increase the adverse neuromuscular activities of Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of myopathy and weakness can be increased when Atracurium besylate is combined with Prednisolone.Approved, Vet Approved
PrednisoneAtracurium besylate may increase the adverse neuromuscular activities of Prednisone.Approved, Vet Approved
PregabalinThe therapeutic efficacy of Atracurium besylate can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PregnenoloneAtracurium besylate may increase the adverse neuromuscular activities of Pregnenolone.Approved, Experimental, Investigational
PrenylaminePrenylamine may increase the neuromuscular blocking activities of Atracurium besylate.Withdrawn
ProcainamideProcainamide may increase the neuromuscular blocking activities of Atracurium besylate.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Atracurium besylate.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Atracurium besylate.Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Atracurium besylate.Approved, Investigational
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Atracurium besylate.Approved
PropiverineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Propiverine.Approved, Investigational
ProscillaridinAtracurium besylate may increase the arrhythmogenic activities of Proscillaridin.Experimental
PseudoephedrineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Pseudoephedrine.Approved
PuromycinPuromycin may increase the respiratory depressant activities of Atracurium besylate.Experimental
PyrantelThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Pyrantel.Approved, Vet Approved
PyridostigmineThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Pyridostigmine.Approved, Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Atracurium besylate.Approved
QuinethazoneQuinethazone may decrease the neuromuscular blocking activities of Atracurium besylate.Approved
QuinidineQuinidine may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational
QuinineQuinine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
RamosetronAtracurium besylate may increase the constipating activities of Ramosetron.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Remifentanil.Approved
RibostamycinRibostamycin may increase the respiratory depressant activities of Atracurium besylate.Approved, Investigational
RimexoloneAtracurium besylate may increase the adverse neuromuscular activities of Rimexolone.Approved
RivastigmineThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Rivastigmine.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Rizatriptan.Approved
RopiniroleAtracurium besylate may increase the sedative activities of Ropinirole.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Atracurium besylate.Approved, Investigational
Secretin humanThe therapeutic efficacy of Human secretin can be decreased when used in combination with Atracurium besylate.Approved
SeletracetamSeletracetam may increase the neuromuscular blocking activities of Atracurium besylate.Investigational
SevofluraneSevoflurane may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Vet Approved
SisomicinSisomicin may increase the respiratory depressant activities of Atracurium besylate.Investigational
SolifenacinThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Solifenacin.Approved
SpironolactoneSpironolactone may increase the neuromuscular blocking activities of Atracurium besylate.Approved
StreptomycinStreptomycin may increase the respiratory depressant activities of Atracurium besylate.Approved, Vet Approved
SufentanilThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Sufentanil.Approved, Investigational
SulpirideAtracurium besylate may increase the anticholinergic activities of Sulpiride.Approved, Investigational
SumatriptanThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Sumatriptan.Approved, Investigational
TacrineThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Tacrine.Investigational, Withdrawn
TapentadolThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Tapentadol.Approved
TerodilineTerodiline may increase the neuromuscular blocking activities of Atracurium besylate.Experimental
TetracyclineThe therapeutic efficacy of Atracurium besylate can be increased when used in combination with Tetracycline.Approved, Vet Approved
TetrahydropalmatineTetrahydropalmatine may increase the neuromuscular blocking activities of Atracurium besylate.Investigational
TetrandrineTetrandrine may increase the neuromuscular blocking activities of Atracurium besylate.Experimental
TilidineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Tilidine.Experimental
TiotropiumAtracurium besylate may increase the anticholinergic activities of Tiotropium.Approved
TixocortolAtracurium besylate may increase the adverse neuromuscular activities of Tixocortol.Approved, Withdrawn
TobramycinTobramycin may increase the respiratory depressant activities of Atracurium besylate.Approved, Investigational
Tolfenamic AcidTolfenamic Acid may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational
TolterodineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Tolterodine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Atracurium besylate.Approved
TorasemideTorasemide may decrease the neuromuscular blocking activities of Atracurium besylate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Atracurium besylate.Approved, Investigational
TranilastTranilast may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational
TriamcinoloneAtracurium besylate may increase the adverse neuromuscular activities of Triamcinolone.Approved, Vet Approved
TrichlorfonThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideTrichlormethiazide may decrease the neuromuscular blocking activities of Atracurium besylate.Approved, Vet Approved
TrichloroethyleneTrichloroethylene may increase the neuromuscular blocking activities of Atracurium besylate.Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Atracurium besylate.Approved
TrimebutineTrimebutine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
TrimethadioneTrimethadione may increase the neuromuscular blocking activities of Atracurium besylate.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Trimethaphan.Approved, Investigational
TropatepineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Tropatepine.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Atracurium besylate.Approved, Investigational
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Atracurium besylate.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Tubocurarine.Approved
TyrothricinThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Tyrothricin.Approved
UlobetasolAtracurium besylate may increase the adverse neuromuscular activities of Ulobetasol.Approved
UmeclidiniumAtracurium besylate may increase the anticholinergic activities of Umeclidinium.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Atracurium besylate.Approved, Investigational
VancomycinThe therapeutic efficacy of Atracurium besylate can be increased when used in combination with Vancomycin.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Vecuronium.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Venlafaxine.Approved
VerapamilVerapamil may increase the neuromuscular blocking activities of Atracurium besylate.Approved
VinpocetineVinpocetine may increase the neuromuscular blocking activities of Atracurium besylate.Investigational
WIN 55212-2WIN 55212-2 may increase the neuromuscular blocking activities of Atracurium besylate.Experimental
XenonXenon may increase the neuromuscular blocking activities of Atracurium besylate.Experimental
ZiconotideZiconotide may increase the neuromuscular blocking activities of Atracurium besylate.Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Zolmitriptan.Approved, Investigational
ZolpidemAtracurium besylate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideZonisamide may increase the neuromuscular blocking activities of Atracurium besylate.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Steven A. Chamberlin, Ashok V. Bhatia, Deborah A. Davis, Keith A. Drengler, "Process for the preparation and isolation of atracurium besylate." U.S. Patent US5684154, issued September, 1995.

US5684154
General References
Not Available
External Links
KEGG Drug
D00758
PubChem Compound
47320
PubChem Substance
46504689
ChemSpider
43068
BindingDB
50149881
ChEBI
2915
ChEMBL
CHEMBL1200527
Therapeutic Targets Database
DAP000105
PharmGKB
PA164776840
RxList
RxList Drug Page
Wikipedia
Atracurium
AHFS Codes
  • 12:20.20 — Neuromuscular Blocking Agents
MSDS
Download (162 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedSupportive CareQuality of Ocular Akinesia (Onset and Duration)1
Not AvailableNot Yet RecruitingSupportive CareFemale Breast Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Baxter International Inc.
Dosage forms
FormRouteStrength
Injection, solutionIntravenous10 mg/mL
Injection, solutionIntravenous100 mg/10mL
Injection, solutionIntravenous50 mg/5mL
SolutionIntravenous10 mg
LiquidIntravenous10 mg
Prices
Unit descriptionCostUnit
Atracurium 10 mg/ml vial0.96USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)85-90Stenlake, J.B., Waigh, R.D., Dewar,G.H., Urwin, J. and Dhar, N.C.; U.S. Patent 4,179,507 December 18,1979; assigned to BurroughsWellcome Company.
water solubilityMiscibleNot Available
Predicted Properties
PropertyValueSource
Water Solubility4.17e-05 mg/mLALOGPS
logP3.34ALOGPS
logP-0.96ChemAxon
logS-7.5ALOGPS
pKa (Strongest Acidic)19.02ChemAxon
pKa (Strongest Basic)-4.1ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count10ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area126.44 Å2ChemAxon
Rotatable Bond Count28ChemAxon
Refractivity280.68 m3·mol-1ChemAxon
Polarizability104.67 Å3ChemAxon
Number of Rings8ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9907
Blood Brain Barrier+0.9367
Caco-2 permeable+0.6226
P-glycoprotein substrateSubstrate0.8276
P-glycoprotein inhibitor IInhibitor0.5282
P-glycoprotein inhibitor IIInhibitor0.6888
Renal organic cation transporterNon-inhibitor0.5447
CYP450 2C9 substrateNon-substrate0.8354
CYP450 2D6 substrateNon-substrate0.6895
CYP450 3A4 substrateSubstrate0.6913
CYP450 1A2 substrateNon-inhibitor0.9225
CYP450 2C9 inhibitorNon-inhibitor0.9468
CYP450 2D6 inhibitorNon-inhibitor0.8816
CYP450 2C19 inhibitorNon-inhibitor0.9107
CYP450 3A4 inhibitorNon-inhibitor0.8359
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9068
Ames testNon AMES toxic0.7032
CarcinogenicityNon-carcinogens0.9241
BiodegradationNot ready biodegradable0.7843
Rat acute toxicity2.5245 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8459
hERG inhibition (predictor II)Non-inhibitor0.5169
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzylisoquinolines. These are organic compounds containing an isoquinoline to which a benzyl group is attached.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Isoquinolines and derivatives
Sub Class
Benzylisoquinolines
Direct Parent
Benzylisoquinolines
Alternative Parents
Benzenesulfonic acids and derivatives / Dimethoxybenzenes / Tetrahydroisoquinolines / 1-sulfo,2-unsubstituted aromatic compounds / Benzenesulfonyl compounds / Phenoxy compounds / Anisoles / Aralkylamines / Alkyl aryl ethers / Dicarboxylic acids and derivatives
show 11 more
Substituents
Benzylisoquinoline / Tetrahydroisoquinoline / Benzenesulfonate / O-dimethoxybenzene / Dimethoxybenzene / Arylsulfonic acid or derivatives / Benzenesulfonyl group / 1-sulfo,2-unsubstituted aromatic compound / Phenoxy compound / Anisole
show 30 more
Molecular Framework
Not Available
External Descriptors
quaternary ammonium salt, organosulfonate salt (CHEBI:2915)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Drug binding
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name
CHRNA2
Uniprot ID
Q15822
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-2
Molecular Weight
59764.82 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Jonsson Fagerlund M, Dabrowski M, Eriksson LI: Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52. doi: 10.1097/ALN.0b013e31819fade3. [PubMed:19417616]

Drug created on June 13, 2005 07:24 / Updated on August 14, 2018 07:24